Projects and Grants

Projects per year 2016 2025

• 5 Active

Projects per year

Search results

• Active

  MT2020-23: A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma

  Janakiram, M.

  Fate Therapeutics, Inc.

  6/1/20 → 5/31/25

  Project: Research project

  • Multiple Myeloma
  • Acute Myeloid Leukemia
  • Multicenter Studies
  • Monoclonal Antibodies

• A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSEEXPANSION STUDY OF NKTR-255 AS A SINGLE AGENT IN RELAPSED OR REFRACTORYHEMATOLOGICAL MALIGNANCIES AND IN COMBINATION WITH DARATUMUMAB AS A SALVAGEREGIMEN FOR MULTIPLE MYELOMA

  Janakiram, M.

  NEKTAR THERAPEUTICS

  12/2/19 → 12/31/24

  Project: Research project

  • daratumumab
  • Hematologic Neoplasms
  • Multiple Myeloma
  • Neoplasms

• A Phase 1/2a Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 (formerly TEV-48573) Administered Intravenously as a Single Agent in Patients With Refractory Multiple Myeloma

  Janakiram, M.

  Takeda Cambridge Ltd.

  8/14/19 → 8/30/24

  Project: Research project

  • Proxy
  • Multiple Myeloma
  • Pharmacokinetics
  • Safety

• Phase I/II Study of Ixazomib and Romidepsin in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL): Big Ten Cancer Research Consortium BTCRC-HEM15-028

  Janakiram, M.

  BIG TEN CANCER RESEARCH CONSORTIUM

  9/1/18 → 8/30/22

  Project: Research project

  • ixazomib
  • romidepsin
  • Peripheral T-Cell Lymphoma
  • Neoplasms

• Open label Dose Escalation Trial of an Adaptive Natural

  Janakiram, M.

  Fate Therapeutics, Inc.

  10/1/16 → 4/24/21

  Project: Research project

  • Acute Myeloid Leukemia
  • Natural Killer Cells
  • Interleukin-2